Copper, Zinc, Selenium, Cadmium and Lead Levels in plasma of Hemodialysis Patients by Shawkia S. A. El-Sherbeny*, Asmaa, M. Abd Allah**, Waleed Massoud
The Egyptian Journal of Hospital Medicine (2006) Vol., 24: 556 –  563                              
                                                                                                                               
 
Copper, Zinc, Selenium, Cadmium and Lead Levels in plasma  
 of Hemodialysis Patients. 
 
Shawkia S. A. El-Sherbeny
*, Asmaa, M. Abd Allah
**,  Waleed Massoud
*** 
 
*Nutritional Biochemistry Department. National Nutrition Institute. 
**Clinical Nutrition Department. National Nutrition Institute. 
***Nephropathy Department-Ahmed Maher Teaching Hospital. 
 
 
Abstract 
 
         Introduction: Hemodialysis patients  are at  risk of developing  trace elements  imbalance 
and increase in heavy metals. Objective:  The objective of this study was to asses plasma levels 
of  copper,  zinc,  selenium,  cadmium  and  lead  of  hemodialysis  patients.  Design:    The  study 
comprised 40  patients aged 27-65 years under regular hemodialysis for 1.8-13 years and 28 
healthy age and sex matched the  control. Copper, zinc, selenium, cadmium and lead plasma 
levels  were  determined  by  atomic  absorption  spectrophotometry.  Results:    Levels  of  copper, 
zinc and selenium were significantly decreased in dialysis patients compared with the control 
group; the percentage decrease was 25.5%, 20.4% and 19.0% for copper zinc and selenium, 
respectively.  Moreover,  cadmium  and  lead  plasma  levels  showed  significant  increases  among 
hemodialysis patients versus their matched controls with percentage of 144.6% and 28.1% for 
cadmium and lead, respectively.  Conclusions: Levels of trace elements are altered and heavy 
metals showed increased plasma levels by hemodialysis. Regular monitoring of trace elements 
and heavy metals in hemodialytic patients is advisable.   
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Introduction:   
 
         Altered  blood  and  tissue  concen-
trations of trace elements have been descr-
ibed  in  patients  with  chronic  renal  failure 
treated  by  hemodialysis  (HD)  (Berlyne, 
1995). The most important factors for this 
alteration are the degree of renal failure and 
the  modality  of  renal  replacement  therapy 
(Vanholder et al., 1996). 
         Copper (Cu) is an important element 
for hemoglobin synthesis, connective tissue 
metabolism  and  bone  development  (Brody, 
1994).  Copper  may  play  a  role  in  the 
antioxidant  defene  system  such  as  coppe-
r/zinc  superoxide  dismutase  (Cu/ZnSOD), 
ceruloplasmin  and  intracellular  thioneins. 
(Linder,  1996).  Serum  copper  tends  to  be 
generally  low  in  patients  treated  with  HD 
(Lee et al., 2000). Suspected copper defic-
iency  was  also  supposed  to  play  a  role  in 
the  pathogenesis  of  anemia  and  growth 
retardation  of  dialyzed  patients.  (D'Haese 
and De Broe, 1996). 
         Zinc  (Zn)  is  an  essential  trace 
element;  it  is  used  by  a  great  number  of 
enzymes,  such  as  alkaline  phosphates, 
superoxide dismutase, protein kinase C and 
carboxypeptidase  A,  B  (Brody,  1994). 
Serum and plasma zinc in HD patients were 
found  either  to  be  normal  (Agenet  et  al., 
1989)  or  more  often  decreased  (Cabral  et 
al., 2005). Zinc depletion was suggested to 
play  a  role  in  the  pathogenesis  of  some 
uremic  symptoms,  e.g.  impotence  (testic-
ular  atrophy),  immunological  impairment, 
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growth  retardation,  abnormalities  of  taste 
(dysgeusia,  anorexia)  and  olfaction  (Zima 
et al., 1999). 
         Selenium  (Se)  is  an  essential  trace 
element with several important roles in the 
human  body:  synthesis  of  thyroid 
hormones;  role  in  antioxidant  mechanisms, 
as  an  essential  component  of  the  antio-
xidant  enzyme  glutathione  peroxidase; 
production of prostaglandins and promotion 
of  growth  and  fertility  (Brody,  1994). 
Selenium is probably  decreased in  plasma, 
erythrocytes  and  white  cells  of  dialyzed 
patients  (Mestek  et  al.,  2002).  Selenium 
deficiency  has  been  implicated  as  contri-
buting to the development of cardiovascular 
disease  (congestive  cardio-myopathy), 
accelerated  atherosclerosis,  skeletal  muscle 
myopathy,  anemia,  infertility  and  deranged 
immune  function  (Zima  et  al.,  1999).  
Almost  all  these  problems  are  common  in 
patients with renal failure. 
         Cadmium  (Cd)  is  toxic  and  lead  to 
growth  retardation,  impairment  reprodu-
ction, hypertension, cancer  and also  decre-
ased zinc, copper and calcium absorption in 
the  gastrointestinal  tract  (Linder,  1991). 
Serum  levels  of  cadmium  in  patients  with 
chronic  renal  failure  were  reported  to  be 
normal (Malecka et al., 1994)), high (Turan 
et al., 1992)) or even decreased (Thomson 
et  al.,  1983).  The  whole  blood  cadmium 
levels were  increased  in  HD  patients  (Hsu 
et al., 1997).  
         Accumulation  of  lead  (Pb)  has  been 
reported in patients with renal failure. In a 
study conducted by Staessen et al. (1992), 
on  a  random  population  of  965  men  and 
1016  women,  the  creatinine  clearance  was 
found to be inversely correlated with blood 
lead values. Furthermore, a 10-fold increase 
in blood lead was associated with a 10-13 
ml/min  reduction  in  creatinine  clearance. 
Thus, the hypothesis that renal impairment 
resulted  in  blood  lead  accumulation  could 
not  be  ruled  out.  In  Egypt,  as  nutritional 
awarness  is  iasufficient  and  environmental 
pollution is high, hemodialysis patients are 
at risk of developing imblavced trace elem-
ent  levels.  The  present  study  was  carried 
out  to  determine  the  concentration  of 
copper,  zinc,  selenium,  cadmium  and  lead 
in plasma of hemodialysis Egyptian patients 
Subjects and methods:  
 
         Forty  patients  with  end  stage  renal 
failure  undergoing  regular  hemodialysis 
were recruited from the outpatient's dialysis 
unit  of  Ahmed  Maher  teaching  hospital, 
Cairo,  Egypt,  during  the  period  from 
November  2004  to  March  2005.  All 
patients  were  on  bicarbonate-dialysis  with 
cellulose  for  duration  of  1.8-13  years 
(4.5±2.4). Their characteristics is illustrated 
in  table  (1).  The  control  group  comprised 
28  age  and  sex  matched  healthy  persons. 
Informed consent was obtained from all the 
participants.  Patients  were  not  taken  any 
constituent  drug  including  copper,  zinc  or 
selenium. 
         Fasting  (12  hours)  venous  blood 
samples  were  collected  from  patients 
(before dialysis) and controls in heparinzed 
tubes. The plasma was separated by centrif-
ugation. Plasma levels of copper, zinc, sele-
nium.  Cadmium  and  lead  were  determined 
according  to  AOAC  (1990),  using  AAS 
Vario 6 atomic absorption spectrometer. 
 
Statistical analysis: 
         The data were subjected to statistical 
analysis  using  computer  programme  SPSS 
(1996).  Independent  t-test  and  one-way 
analysis of  variance  (ANOVA)  were  used, 
the difference was considered significant at 
p-value< 0.05 (Zar, 1984).  
 
Results:  
 
         The  HD  patients  had  significantly 
lower plasma levels of copper (25.5%), zinc 
(20.5%)  and  selenium  (19.0%)  than  the 
healthy control group (table 2).   
         The  mean  plasma  levels  of  copper, 
zinc  and  selenium  of  HD  patients  were 
within  the  normal  values.  However,  5 
(12.5%), 8 (20%) and 11 (27.5%) patients 
were  classified  as  copper,  zinc  and 
selenium deficient, respectively. 
         With  regard  to  the  measured  heavy 
metals,  both  cadmium  and  lead  (table  3) 
were  significantly  elevated  in  HD  patients 
as  compared  with  the  control  group;  the 
percentage  increase  was  144.6%  and  28% 
for cadmium and lead, respectively.  Copper, Zinc, Selenium, Cadmium and………. 
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Table (1): Characteristics of Hemodialysis Patients. 
 
                          
                                  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table  (2):  Plasma  levels  of  copper,  zinc  and  selenium    of  the  HD  patients  and  control. 
(Mean±S.D) 
          
* Significant at   P < 0.05  
 NV= Normal value. (Versiek and Cornetis, 1980) 
 
Table (3): Plasma levels of cadmium and lead of the HD patients and  control. (Mean±S.D) 
 
* Significant at   P < 0.05  
NV= Normal value (Versiek and Cornetis, 1980). 
 
Discussion:  
 
         Plasma  levels  of  copper  were  found 
significantly  lower  in  dialysis  patients 
compared  with  normal  controls.  These 
results  are  in  keeping  with  a  number  of 
studies  reporting  lower  copper  plasma 
concentrations  in  hemodialysis-treated 
patients (Lee et al., 2000 and Weissgarten 
et  al.,  2001).  .On  the  other  hand,  high 
(Hsieh et al., 2006) or normal plasma levels 
of  copper  (Berger  et  al.,  2004)  have  been 
reported. Decreased plasma copper may in 
some  dialyzed  patients  correlate  with 
erythrocyte  superoxide  dismutase  activity 
(Vandecateele  et  al.,  1993).  However, 
Variable   
Age (mean±SE)  49.5±11.3 years 
Sex: Males 
       Females 
24 (60%) 
16 (40%) 
Dialysis time (hours/session)  6 hours 
Kt/v (mean±SE)  1.12±0.23 
Causes of renal disease:  
Hypertensive nephropathy 
Diabetic  nephropathy  
Pyelonephritis  
Renal stones 
Polycystic kidney 
Hyperthyroidism 
Unknown causes. 
 
16 (40%) 
8 (20%) 
4 (10%) 
4 10%) 
2 (5%) 
1 (2.5%) 
5 (12.5%) 
parameters  HD patients 
(n=40) 
Control 
(n=28) 
% change 
Plasma  copper (NV=80-
140 ug/dl) 
99.195±28.30*  133.066±27.94  - 25.5% 
Plasma zinc (NV=70-140 
ug/dl) 
98.123±13.20*  123.233±23.15  - 20.4% 
Plasma selenium (NV= 6-
17 ug/dl) 
7.427±1.87*  9.171±1.87  - 19.0% 
parameters  HD patients 
(n=40) 
Control 
(n=28) 
% change 
Plasma cadmium (NV= 0-
2 ug/l) 
0.592±0.179
*  0.242±0.092  + 144.6 
Plasma  Lead (NV=0.8-2.5 
ug/l) 
1.237±0.399
*  0.965±0.281  + 28.2 Shawkia S. A. El-Sherbeny et al  
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Weissgarten et al. (2001) found that plasma 
ceruloplasmin  levels  as  well  as  cerulopl-
asmin-bound copper fraction were signific-
antly  lower  in  HD  patient  compared  with 
normal  subjects,  and  that  the  free  copper 
fraction  was  significantly  higher  in  this 
patient  group.  This  would  tend  to  suggest 
that ceruloplasmin capacity to bind copper 
was decreased in uremic plasma.  
         Previuos  reports  have  indicated  a 
significant decrease in  plasma zinc concen-
tration  in  hemodialysis  patients  as  comp-
ared  with  healthy  controls  (Cabral  et  al., 
2005 ; Hsieh et al., 2006). The result of the 
present  study  agreed  with  these  findings. 
However, in another study, zinc levels were 
found to be normal in HD patients (Agenet 
et al., 1989).  
         The observed  decreased plasma zinc 
levels  in  HD  patients    may  be  connected 
with  low  zinc  intake,  dietary  restriction  in 
association  with  augmented  zinc  excretion 
which  may  be  caused  by  either  decreased 
zinc absorption or increased its excretion or 
both  by  gut  (  Kimmel  et  al.,  1988  ;  
Mahajan et al., 1989). Moerover, affinity of 
zinc  to  albumin  in  uremic  patients  was 
found  to  be  decreased  (Foote  and  Hinks, 
1988). However,  the  decreased  serum  zinc 
concentration found in HD patients may be 
related  to  a  redestribution  of  zinc  in  the 
tissues and not to its true deficiency beca-
use in most studies reporting a reduction in 
serum zinc  levels,  the  concentration  in  red 
blood  cells  is  elevated  (Peuchant  et  al., 
1994). 
         In  this  study,  selenium  level  was 
significantly  lower  in  HD  patients  than 
control  group.  Similar  results  have  been 
reported in previous  studies (Yavuz  et  al., 
2004 ; Hsieh et al., 2006 ). These findings 
seemed to  be  justifiable  because  in  human 
among other organs, the kidney contains the 
highest  level  of  selenium  (Zachara  et  al., 
2001a)  and  plays  an  important  regulatory 
role  in  homeostasis  of  the  element 
(Robinson  et  al.,  1985).  Glutathione  pero-
xidase is a selenium dependent glycosylated 
enzyme synthesized primarilty in the  prox-
imal tubular cells of the kidney (Avissar et 
al.,  1994).  Decreased  activity  of  this 
enzyme has been detected in red blood cells 
and plasma of chronic renal failure patients 
(Zachara  et  al.,  2000&  2001b).  Renal 
failure  itself  may  have  some  influence  on 
selenium  concentration  probably  through 
decreased  absorption  in  the  small  intestine 
(Bonomini  et  al.,  1996).  Moreover,  a  low 
dialysate  concentration  of  selenium  may 
result  in  its  removale  during  HD  with 
resulting  in  deficiency  (D'Haese  et  al., 
1996). 
         The  trace  elements  status  in  chronic 
renal  failure  patients  may  also  be 
influenced  by  residual  renal  function,  the 
dialyzer  membrane  and  size,  the  nature  of 
the water used for preparation of dialysate, 
the  method  of  purification  and  the 
composition  of  dialysis  concentrate  (Gault 
et  al.,  1991).  Efficient  water  purification 
processes and ultra-low dialysate levels of a 
number  of  trace  elements  may  lead  to  a 
deficiency  in  some  essential  elements 
(D'Haese et al., 1996). However, Padovese 
et al. (1992) found that the concentration of 
copper, zinc and selenium in HD dialysate 
were low and suggested that these elements 
should  be  considered  more  carefully  in 
studies  determining  the  profiles  in  body 
fluids  and  tissues  of  uremic  patients 
undergoing regular dialysis treatment.     
         With regard to heavy metals, Plasma 
cadmium  levels  of  HD  patients  were 
significantly  higher  than  healthy  control. 
This  results  agreed  with  other  reports 
(Turan  et  al.,  1992  &  Lee  et  al.,  2000). 
Furthermore, increased tissue concentration 
of  cadmium  in  the  liver  and  spleen  and 
decreased  concentrations  in  the  kidneys 
were  detected  in  HD  patients  (Smythe  et 
al., 1982). 
The  source  of  cadmium  in  HD 
patient  are  currently  unknown,  but  enviro-
nmental  factors  such  as  cosmetics  cont-
aining heavy metals, polluted water and air 
may  be  involved  (Klein  et  al.,  1972  & 
Sondheimer  et  al.,  1988).  In  healthy 
individual,  normal  functioning  kidneys 
eliminate  toxic  elements  from  the  body. 
However, in renal failure, declining  kidney 
functions  leads  to  an  accumulation  of 
potentially  nephrotoxic  elements  which 
may contribute to the deterioration of renal 
function (Vanholder et al., 1996).  
         Many  investigators  have  described 
increased  levels  of  lead  in  renal  failure Copper, Zinc, Selenium, Cadmium and………. 
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patients (D’Haese et al., 1999 ; Kim et al., 
2006). The results of the present study are 
consistent with these reports.  The kidney is 
the  main  organ  excreting  lead  from  pool. 
Thus,  lead  burdens  have  a  tendency  to  be 
accumulated  in  the  patients  with  renal 
failure (Silbergeld et al., 1988). In patients 
with  end  stage  renal  disease,  hyperpar-
athyroidism,  abnormal  vitamin  D 
metabolism,  and  consequent  osteoporosis 
have  frequently  been  observed  (Llach  and 
Bover, 2000). Taken together with the lack 
of  renal  excretion  and  stimulated  bone 
resorption,  may  confirm  the  increased 
blood  levels  of  lead  in  patients  with  end 
stage  renal  disease.  Major  forms  of  lead 
poisoning  are  colic,  hypertension,  and 
neuropathy.  It  is  not  easy  to  define  these 
symptoms  in  patients  with  end  stage  renal 
disease because uremia itself may cause of 
and/or  aggravate  these  symptoms. 
Furthermore,  chronic  lead  poisoning  may 
be a cause of end stage renal disease (Thun 
et al., 1982).  
However,  increased  heavy  metals 
concentrations in  renal  failure  patients  can 
result  from  excessive  homeopathic  intake, 
industrial  or  environmental  exposure,  and 
inhalation  of  cigarette  smoke,  administ-
ration  of  parental  fluids  or  blood  contact 
with  contaminated  dialysate  (Vanholder  et 
al., 1996). 
         In conclusion; levels of trace elements 
are  altered  and  heavy  metals  showed 
increased  plasma  levels  by  hemodialysis. 
Regular  monitoring  of  trace  elements  and 
heavy  metals  in  hemodialytic  patients  is 
advisable.   
 
Recommendation  
 
         Further  investigation  on  large  scale 
on  Egyptian  hemodialysis  patients  should 
be carried out to assess the real situation of 
these elements 
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 ىضره اهزلاب ىف صاصرلا و مويهداكلا و موينيليسلا و كنسلا و شاحنلا سيكرت
يولكلا ليسغلا  
 
ىنيبرشلا نيلحلا دبع ديس ةيقوش
1   ةللا دبع دووحه ءاوسأ ،
2   دوعسه ديلو ،
3  
1 -   ةّذغتلا ءاْمْم مسق -   ةّذغتلل ِمٌقلا ديعملا . 2 -    ةْنْنْلملإا ةّذغتلا مسق -    ِمٌقلا ديعملا
ةّذغتلل  .  
3 -    مسق َلنلا -   ِمْلعتلا رىام دمحأ َفشتسم .  
 
  
  ةهدقه  :  ً ةرقْقدلا رراانعلا لااٌرا تدرد ررطخل ٌُلنلا لْسغلا َضرم ضرعتّ
ةررلْق لا ل اررعملا نررعم ٌٍتررسم تاررفافا للذررم  . ةررسا دلا ارررا هرره مرررغلا   : ْررْعا ٌررى ن  
  اررما م َرر   اررارلا ً تٌْم اررنلا ً تٌْنْلْررسلا ً لرريسلا ً كاررانلا نررم لررم ٌٍتررسم
سغلا َضرم ٌُلنلا لْ  . ةبرجتلا :    ةر افدلا اذرى ِر  كرتشا 44    لرمعم لٌرمٌقّ ارضّرم
 للذم ً مظتنم لنشم ٌُلم لْسغ 22    ءااالأا نم ( ةطماض ةدٌمجمم   )  َ  مييٌلثامّ
سنجلا ً نسلا   . ٍفذرلا  اررتماا ااريلا تادختر ام ةقمارسلا رراانعلا كارْق مرا درق ً   .
جئاتنلا  : نلا نم لم ٌٍتسم َ  ٌُنعم ضافخيا دلاً دق  َر  تٌْنْلْرسلا ً لريسلا ً كاا
 ةبسنم ءااالأا مىرئاظنم ةيفاقملام َضرملا اما م 25.5 %  , 24.5 %  , 1..4  %  لرنل
ِلاٌرتلا َررلد تٌْنْلْررسلا ً لريسلا ً كاررانلا نرم  .  ً تٌْم اررنلا  نررم لرم سررْمرا  اا اررمم
 ةطمارضلا ةردٌمجملا نرد ةرٌّنعم ا ارّا ٌُرلنلا لْرسغلا َرضرم ارما م َ   اارلا
 ةبسنم 144.4 %  , 22.1  % ِلاٌرتلا َرلد  ارارلا ً تٌْم ارنلا نرم لرنل   .  اتنترسلاا  :
 ةررْلمعم رث ررتّ ةررلْق لا ل اررعملا ً ةررقْقدلا ررراانعلا سررْمرا لأ ةرر افدلا اذررى نررم متنتررسي
مظتنم لنشم َضرملا ءاؤيل راانعلا هذى رّدقا متّ لأ بجّ ويأ ً ٌُلنلا لْسغلا  .  
 